Clinical Trial Update: Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (Prevnar 13) completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2011-05-30